1. The lipoprotein-associated phospholipase A2 inhibitor Darapladib sensitises cancer cells to ferroptosis by remodelling lipid metabolism.
- Author
-
Oh, Mihee, Jang, Seo Young, Lee, Ji-Yoon, Kim, Jong Woo, Jung, Youngae, Kim, Jiwoo, Seo, Jinho, Han, Tae-Su, Jang, Eunji, Son, Hye Young, Kim, Dain, Kim, Min Wook, Park, Jin-Sung, Song, Kwon-Ho, Oh, Kyoung-Jin, Kim, Won Kon, Bae, Kwang-Hee, Huh, Yong-Min, Kim, Soon Ha, and Kim, Doyoun
- Subjects
PHOSPHOLIPASE A2 ,LIPID metabolism ,CANCER cells ,METABOLIC regulation ,ARACHIDONIC acid ,PHOSPHOLIPASES ,CYTOPLASM - Abstract
Arachidonic and adrenic acids in the membrane play key roles in ferroptosis. Here, we reveal that lipoprotein-associated phospholipase A2 (Lp-PLA2) controls intracellular phospholipid metabolism and contributes to ferroptosis resistance. A metabolic drug screen reveals that darapladib, an inhibitor of Lp-PLA2, synergistically induces ferroptosis in the presence of GPX4 inhibitors. We show that darapladib is able to enhance ferroptosis under lipoprotein-deficient or serum-free conditions. Furthermore, we find that Lp-PLA2 is located in the membrane and cytoplasm and suppresses ferroptosis, suggesting a critical role for intracellular Lp-PLA2. Lipidomic analyses show that darapladib treatment or deletion of PLA2G7, which encodes Lp-PLA2, generally enriches phosphatidylethanolamine species and reduces lysophosphatidylethanolamine species. Moreover, combination treatment of darapladib with the GPX4 inhibitor PACMA31 efficiently inhibits tumour growth in a xenograft model. Our study suggests that inhibition of Lp-PLA2 is a potential therapeutic strategy to enhance ferroptosis in cancer treatment. Ferroptosis is an iron-dependent cell death mechanism that is emerging as a target for cancer therapy. Here, the authors find that lipoprotein-associated phospholipase A2 modulates ferroptosis resistance by controlling phospholipid metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF